Cartesian Therapeutics (RNAC) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 Jun, 2026Opening remarks and agenda
CEO and Chairman welcomed attendees, introduced board members, and outlined meeting procedures.
Independent auditors from Ernst & Young were introduced and made available for questions.
Corporate governance
Inspector of Election from Broadridge Financial Solutions confirmed a quorum and proper delivery of meeting materials.
Only stockholders of record as of April 14, 2026, or valid proxy holders, were eligible to vote.
Voting was conducted electronically, with polls open during the meeting.
Board and executive committee updates
Election of three Class I directors for terms expiring at the 2029 annual meeting was proposed.
Board unanimously recommended all director nominees.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cartesian Therapeutics
- Q2 2026 net income was $15.8M, with a six-month net loss of $23.4M and cash runway into 2028.RNAC
Q2 2026 - Q1 2026 net loss rose to $39.2M as R&D and CVR liability increased; cash at $120.4M.RNAC
Q1 2026 - Virtual annual meeting to vote on directors, pay, and auditor ratification June 12, 2026.RNAC
Proxy filing - 2026 proxy covers director elections, executive pay, auditor ratification, and governance priorities.RNAC
Proxy filing - Descartes-08 delivers durable, outpatient mRNA cell therapy for autoimmune diseases, targeting major US markets.RNAC
Corporate presentation - Net loss rose to $130.3M in 2025 as pivotal Descartes-08 trials advanced; cash runway extends to mid-2027.RNAC
Q4 2025 - Up to $400M in securities, including $100M at-the-market stock, to fund mRNA autoimmune pipeline.RNAC
Registration Filing - Over 11 million shares registered for resale as mRNA cell therapy pipeline advances.RNAC
Registration Filing - Resale registration for 6.2M+ shares as mRNA cell therapy pipeline advances in autoimmune disease.RNAC
Registration Filing